Researchers utilized patient-derived xenografts transplanted into in vivo mouse models to discover that the Aryl hydrocarbon Receptor (AhR), a transcription factor, becomes constitutively activated in these resistant melanoma cells, thereby driving treatment resistance [95]. Here, AHR is linked to melanoma.